Wegovy: The Weight Loss Drug That Reduces Heart Attack Risk
Novo Nordisk's obesity drug Wegovy has demonstrated significant cardiovascular benefits beyond weight loss in a landmark trial called Select. The trial revealed that Wegovy reduced the risk of heart attacks by 28% among patients already taking heart medications, while also reducing cardiovascular-related deaths by 15% and strokes by 7%. The overall risk reduction in heart problems was 20%, translating to 15 complications prevented for every 1,000 patients treated. The trial's findings mark a significant milestone for the cardiology field and may help in convincing insurers to increase access to the drug.